Depression in cancer: The many biobehavioral pathways driving tumor progression
Köhler, C. A.
Fernandes, B. S.
Carvalho, A. F.
SourceCancer treatment reviews
Google Scholar check
MetadataShow full item record
Major Depressive Disorder (MDD) is common among cancer patients, with prevalence rates up to four-times higher than the general population. Depression confers worse outcomes, including non-adherence to treatment and increased mortality in the oncology setting. Advances in the understanding of neurobiological underpinnings of depression have revealed shared biobehavioral mechanisms may contribute to cancer progression. Moreover, psychosocial stressors in cancer promote: (1) inflammation and oxidative/nitrosative stress; (2) a decreased immunosurveillance; and (3) a dysfunctional activation of the autonomic nervous system and of the hypothalamic–pituitaryadrenal axis. Consequently, the prompt recognition of depression among patients with cancer who may benefit of treatment strategies targeting depressive symptoms, cognitive dysfunction, fatigue and sleep disturbances, is a public health priority. Moreover, behavioral strategies aiming at reducing psychological distress and depressive symptoms, including addressing unhealthy diet and life-style choices, as well as physical inactivity and sleep dysfunction, may represent important strategies not only to treat depression, but also to improve wider cancer-related outcomes. Herein, we provide a comprehensive review of the intertwined biobehavioral pathways linking depression to cancer progression. In addition, the clinical implications of these findings are critically reviewed. © 2016 Elsevier Ltd
Showing items related by title, author, creator and subject.
Targeting IL13Ralpha2 activates STAT6-TP63 pathway to suppress breast cancer lung metastasis Papageorgis, P.; Ozturk, S.; Lambert, A. W.; Neophytou, Christiana M.; Tzatsos, Alexandros; Wong, C. K.; Thiagalingam, S.; Constantinou, Andreas I. (2015)Introduction: Basal-like breast cancer (BLBC) is an aggressive subtype often characterized by distant metastasis, poor patient prognosis, and limited treatment options. Therefore, the discovery of alternative targets to ...
Soluble interleukin-2 receptors in patients with advanced colorectal carcinoma Pavlidis, Nicholas; Nikolaides, C.; Bairaktari, Eleni Th; Kalef-Ezra, J. A.; Athanasiades, A.; Seferiadis, C.; Fountzilas, George (1996)The levels of soluble interleukin-2 receptors (sIL-2R) were measured in the serum of 52 patients with advanced colorectal carcinoma and compared to CEA and CA 19-9 levels. Twenty-five normal, age and sex-matched individuals ...
Serum soluble interleukin-2 receptors in epithelial ovarian cancer patients Pavlidis, Nicholas; Bairaktari, Eleni Th; Kalef-Ezra, J. A.; Nikolaides, C.; Seferiadis, C.; Fountzilas, George (1995)The levels of soluble interleulkin-2 receptors (sIL-R2) were measured in the serum of 52 patients with epithelial ovarian carcinoma as well as in 25 age and sex-matched normal controls. The mean serum level of sIL-2R was ...